Actively Recruiting
Randomized Study of Oral GV-100 Dosing with Food Effect and Drug Interaction in Healthy Adults
Led by Gilva Therapeutics Inc. · Updated on 2026-08-26
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GV-100 in a first-in-human, multi-part clinical trial to study its safety, tolerability, pharmacokinetics, food effects, and potential drug interactions in healthy adults. This phase 1 study includes participants aged 18 to 65 years who are non-smokers with specific body mass index and weight requirements. The study is randomized, double-blind, and placebo-controlled, sponsored by Gilva Therapeutics Inc., focusing on treatment use of GV-100. The study is divided into four parts Single Ascending Dose SAD, Multiple Ascending Dose MAD, Food Effect FE, and Drug-Drug Interaction DDI. Participants receive oral doses of GV-100 or a matched placebo. Each part examines different dosing schedules and conditions, including food intake and interactions with other drugs, to understand how GV-100 behaves in the body under various scenarios. Participants undergo screening to confirm eligibility, followed by dosing periods according to study parts. Assessments include monitoring adverse events up to 7 weeks, measuring maximum plasma concentration and area under the curve for GV-100 at specific timepoints. Safety tests involve physical exams, laboratory tests, vital signs, and ECGs. The study duration varies by part but includes close monitoring to evaluate the drugs safety profile and pharmacokinetic parameters.
CONDITIONS
Brief Title
A Phase 1 Study of Single and Multiple Ascending Doses of GV-100
Research Team
I
I-Chu Tsai
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here